Viewing StudyNCT06540729

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-10-26 @ 3:37 PM
Last Modification Date: 2024-10-26 @ 3:37 PM
Study NCT ID: NCT06540729
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-08-02
Brief Title: Disitamab Vedotin RC48 in Combination With AK104 PD-1CTLA-4 Bispecific and Bevacizumab for the Treatment of Recurrent and Persistent Clear Cell Ovarian Cancer a Single-arm Phase II Multicenter Study DAB OCC Study
Sponsor: None
Organization: None
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Keywords: